Article ID Journal Published Year Pages File Type
4000247 Urologic Oncology: Seminars and Original Investigations 2012 5 Pages PDF
Abstract

Castrate resistant prostate cancer is a disease state which, counterintuitively, can be successfully treated with additional therapy directed at inhibition of androgen synthesis and/or interfering with the activity of the androgen receptor. Novel androgen biosynthesis inhibitors and antiandrogens are now being tested in large phase 3 clinical trials to clarify their role in the treatment of men who have failed traditional medical castration, with or without currently available nonsteroidal antiandrogens. A renewed interest in studying parenteral delivery of estrogens may provide evidence to revisit the initial medical therapy for advancing prostate cancer.

Related Topics
Health Sciences Medicine and Dentistry Oncology
Authors
,